Effect of metformin in patients with concurrent asthma and metabolic syndrome

Effect of metformin on outcomes of hyperglycemia, inflammatory markers, asthma control test (ACT) and spirometry in patients with concurrent asthma and metabolic syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220305054199N1

Enrollment

110

Registered

2022-11-01

Start date

2022-04-03

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Asthma. Condition 2: Metabolic Syndrome.

Interventions

Intervention 1: Intervention group: Patients receiving standard treatment for severe asthma attacks, according to the GINA guideline, based on random allocation using blockade, are treated with metfor

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with concurrent asthma and metabolic syndrome

Exclusion criteria

Exclusion criteria: Patients with COPD, hypercapnic respiratory failure, bronchiectasis and respiratory system cancers Patients with diabetes People at high risk of malnutrition Patients with renal failure with creatinine clearance less than 30 cc per minute Heart Failure class 4 Hemoglobinopathy includes thalassemia major and intermedia and sickle cell anemia severe liver failure Patient with severe sepsis Patient with cancer

Design outcomes

Primary

Measure	Time frame
Capillary blood glucose concentration and HbA1C. Timepoint: Before meals and two hours after breakfast at the beginning of hospitalization and discharge and one and three months after discharge. Method of measurement: Using Pars Azmoon Kit.;The rate of asthma attacks leads to emergency room visits and hospitalization. Timepoint: At the time of hospitalization and one and three months after hospitalization. Method of measurement: Asthma control test (ACT) and spirometry and clinical history.;The rate of inflammatory markers. Timepoint: At the time of hospitalization and discharge and one and three months after discharge. Method of measurement: Measurement of C-reactive protein (CRP) levels.;HbA1C. Timepoint: At the time of hospitalization and one and three months after hospitalization. Method of measurement: Using Pars Azmoon Kit.	—

Measure

Time frame

Capillary blood glucose concentration and HbA1C. Timepoint: Before meals and two hours after breakfast at the beginning of hospitalization and discharge and one and three months after discharge. Method of measurement: Using Pars Azmoon Kit.;The rate of asthma attacks leads to emergency room visits and hospitalization. Timepoint: At the time of hospitalization and one and three months after hospitalization. Method of measurement: Asthma control test (ACT) and spirometry and clinical history.;The rate of inflammatory markers. Timepoint: At the time of hospitalization and discharge and one and three months after discharge. Method of measurement: Measurement of C-reactive protein (CRP) levels.;HbA1C. Timepoint: At the time of hospitalization and one and three months after hospitalization. Method of measurement: Using Pars Azmoon Kit.

—

Secondary

Measure	Time frame
Body mass index. Timepoint: At the beginning of hospitalization and one and three months after starting metformin. Method of measurement: By a doctor.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHosein Mehravaran

Mazandaran University of Medical Sciences

hmehravaran@mazums.ac.ir+98 11 3337 3689

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026